journal article·2020-01-01Open access

Protective effects of isorhynchophylline against silicon-dioxide-induced lung injury in mice

Min Qiu, Zheng Yang, Mengni Bian, Changxiao Liu, Yunshan Zhao, Quanli Liu

Abstract

Inhalation of silicon dioxide (SD) results in pulmonary inflammatory responses and fibrosis. Isorhynchophylline (Isorhy) is the main alkaloid in the traditional Chinese herb Tripterygium wilfordii, which is reported to have anti-inflammatory activities in the nervous system. However, the effects of Isorhy on SD-induced pulmonary inflammation and fibrosis in mice are unknown. Male mice were exposed to a single dose of SD (2.5 mg/kg, intranasal inoculation) to induce pulmonary fibrosis (PF). The mice were woken up and immediately treated with Isorhy (20 mg/kg, intraperitoneal injection) for 14 or 42 days. The effects of Isorhy on inflammatory responses and lung fibrosis induced by SD were then investigated. After the 14-day treatment, there was a significant reduction in inflammatory cell infiltration in the lungs of mice, with reduced recruitment of inflammatory cells to the lungs. The concentration of pro-inflammatory factors in the bronchoalveolar lavage fluid was reduced, which alleviated inflammatory injury in the lung tissue. After the 42-day treatment, Isorhy alleviated inflammation and inhibited the release of fibrogenic factors in mice with PF. Isorhy also significantly reduced collagen deposition in the lung tissues of mice. Isorhy has the ability to reduce inflammatory responses and fibrosis associated with SD-induced acute lung injury.
Source: europepmc · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis · Occupational and environmental lung diseases · Occupational exposure and asthma

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Cardiovascular Diseases, First Affiliated Hospital of Baotou Medical College

Baotou Medical College

Department of Pharmacy, Baotou Medical College

Tianjin Institute of Pharmaceutical Research

Funding

National Natural Science Foundation of China · Natural Science Foundation of Inner Mongolia, China · Scientific Technology Plan Project of Inner Mongolia, China · Academician Expert Workstation on Pharmacodynamic, Pharmacokinetics and Safety Evaluation Research of Mongolian Medicines · Science Foundation of Baotou Medical College, China

References (43)

Show source-provided references
1. 10.1016/j.ejphar.2008.06.04610.1016/j.ejphar.2008.06.046 ↗
2. 10.5620/eht.e201801410.5620/eht.e2018014 ↗
3. 10.1080/14656566.2017.138338210.1080/14656566.2017.1383382 ↗
4. 10.1016/j.coph.2013.03.01510.1016/j.coph.2013.03.015 ↗
5. 10.1016/S0140-6736(12)61144-110.1016/S0140-6736(12)61144-1 ↗
6. 10.2147/TCRM.S6971610.2147/TCRM.S69716 ↗
7. 10.1073/pnas.141511111210.1073/pnas.1415111112 ↗
8. 10.1016/j.toxlet.2019.07.00810.1016/j.toxlet.2019.07.008 ↗
9. 10.1165/ajrcmb.15.2.870348410.1165/ajrcmb.15.2.8703484 ↗
10. 10.1097/01.mcp.0000152998.11335.2410.1097/01.mcp.0000152998.11335.24 ↗
11. 10.1007/s00204-013-1063-z10.1007/s00204-013-1063-z ↗
12. 10.1016/S0140-6736(12)60235-910.1016/S0140-6736(12)60235-9 ↗
13. 10.1016/j.lfs.2019.03.01710.1016/j.lfs.2019.03.017 ↗
14. 10.1186/s13287-018-0846-910.1186/s13287-018-0846-9 ↗
15. 10.1080/15563650.2018.147952710.1080/15563650.2018.1479527 ↗
16. 10.1016/j.fitote.2012.02.01010.1016/j.fitote.2012.02.010 ↗
17. 10.1007/s00210-003-0854-910.1007/s00210-003-0854-9 ↗
18. 10.1096/fj.201802743RR10.1096/fj.201802743RR ↗
19. 10.1016/j.intimp.2009.09.01010.1016/j.intimp.2009.09.010 ↗
20. 10.1038/s41598-018-36712-610.1038/s41598-018-36712-6 ↗
21. 10.4049/jimmunol.162.10.628410.4049/jimmunol.162.10.6284 ↗
22. 10.1136/jcp.41.4.46710.1136/jcp.41.4.467 ↗
23. 10.1111/j.1440-1843.2008.01450.x10.1111/j.1440-1843.2008.01450.x ↗
24. 10.1378/chest.06-192710.1378/chest.06-1927 ↗
25. 10.1111/jphp.1230810.1111/jphp.12308 ↗
26. 10.1016/j.biopha.2019.10904710.1016/j.biopha.2019.109047 ↗
27. 10.1016/j.freeradbiomed.2007.12.02710.1016/j.freeradbiomed.2007.12.027 ↗
28. 10.1097/ACI.0b013e32802bf8a510.1097/ACI.0b013e32802bf8a5 ↗
29. Davis GS, Pfeiffer LM, Hemenway DR. Persistent overexpression of interleukin-1beta and tumor necrosis factor-alpha in murine silicosis. J Environ Pathol Toxicol Oncol. 1998;17(2):99–114.
30. 10.1080/0190214090275929010.1080/01902140902759290 ↗
31. 10.1164/ajrccm.164.3.200714910.1164/ajrccm.164.3.2007149 ↗
32. 10.4049/jimmunol.157.6.250610.4049/jimmunol.157.6.2506 ↗
33. 10.1016/j.ejphar.2004.07.04710.1016/j.ejphar.2004.07.047 ↗
34. 10.1111/j.1582-4934.2008.00647.x10.1111/j.1582-4934.2008.00647.x ↗
35. 10.1084/jem.170.3.65510.1084/jem.170.3.655 ↗
36. 10.1165/rcmb.2007-0299OC10.1165/rcmb.2007-0299OC ↗
37. 10.1164/ajrccm.163.6.200606410.1164/ajrccm.163.6.2006064 ↗
38. 10.1111/j.1365-2222.2004.02013.x10.1111/j.1365-2222.2004.02013.x ↗
39. 10.1172/JCI20041960310.1172/JCI200419603 ↗
40. Mauviel A. Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol Med. 2005;117:69–80.
41. 10.1016/j.cytogfr.2004.03.00610.1016/j.cytogfr.2004.03.006 ↗
42. 10.1186/rr16210.1186/rr162 ↗
43. 10.3389/fphar.2017.0051310.3389/fphar.2017.00513 ↗